1236303-15-3Relevant articles and documents
Catalyst-free direct C-H trifluoromethylation of arenes in water-acetonitrile
Wang, Dangui,Deng, Guo-Jun,Chen, Shiya,Gong, Hang
supporting information, p. 5967 - 5970 (2018/06/06)
We describe a mild and practical strategy for the catalyst-free trifluoromethylation of arenes using the inexpensive solid sodium triflinate (Langlois' reagent, NaSO2CF3) as a trifluoromethyl (CF3) source and solid sodium
CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS
-
Page/Page column 22, (2011/04/14)
The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.
TETRAHYDRO-PYRAN DERIVATIVES
-
Page/Page column 15, (2011/08/08)
The present invention relates to a compound of formula I wherein R1/R2 are independently from each other hydrogen, (CR2)o-cycloalkyl, optionally substituted by lower alkyl or hydroxy, or are lower alkyl or heterocycloalkyl, and o is 0 or 1; andR may be the same or different and is hydrogen or lower alkyl; orR1 and R2 may form together with the N atom to which they are attached a heterocycloalkyl group, selected from the group consisting of pyrrolidinyl, piperidinyl, 3-aza-bicyclo[3.1.0]hex-3-yl or 2-aza-bicyclo[3.1.0]hex-2-yl, which are optionally substituted by hydroxy;R3 is S-lower alkyl, lower alkyl, lower alkoxy or cycloalkyl;R3′ is hydrogen, lower alkyl substituted by halogen, lower alkyl or lower alkoxyR4 is lower alkyl substituted by halogen, lower alkyl or lower alkoxy;X is —O— or —CH2—;X′ is —O— or —CH2—; with the proviso that one of X or X′ is always —O— and the other is —CH2—; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. It has been found that the compounds of formula I are good inhibitors of the glycine transporter 1 (GlyT-1) and therefore they may be used for the treatment of schizophrenia.
